Structure via PubChem · Public domain (PubChem)
linagliptin
Sign in to saveAlso known as BI-1356, Tradjenta®, BI 1356, (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet. Linagliptin is a dipeptidyl peptidase-4 inhibitor that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is taken by mouth.
Chemical data
- Formula
- C25H28N8O2
- Molecular weight
- 472.5 g/mol
- IUPAC name
- 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
- SMILES
- CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
- InChIKey
- LTXREWYXXSTFRX-QGZVFWFLSA-N
- XLogP
- 1.9
- Polar surface area
- 113 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Research
1,272 papers- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.Diabetes care · 2015
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.JAMA · 2019
- Linagliptin: A comprehensive profile.Profiles of drug substances, excipients, and related methodology · 2025
- Linagliptin safety profile: A systematic review.Primary care diabetes · 2018
- Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.Drugs · 2015
via PubMed
~2 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Side effects
- Mechanism of action
- Names
- See also
- References
- External links
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet. Linagliptin is a dipeptidyl peptidase-4 inhibitor that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is taken by mouth.
Common side effects include inflammation of the nose and throat. Serious side effects may include angioedema, pancreatitis, joint pain. Use in pregnancy and breastfeeding is not recommended.
Excerpted from Wikipedia’s “linagliptin” article, available under the CC BY-SA 4.0 licence.